Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses

Basnet, Sijan; Tachamo, Niranjan; Dhital, Rashmi; Tharu, Biswaraj

doi:10.1080/20009666.2018.1475188

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as an entity, it is frequently missed as only 21 of the 51 cases were initially recognized as DPE by clinicians on admission; all cases were eventually correctly identified by an Infectious Diseases physician or by the IDCP. The missed cases all received broad-spectrum antibiotics for presumed hospital-acquired pneumonia, which meant that the daptomycin was discontinued anyway, helping to treat the underlying problem [ 11 ]. Unfortunately, several patients required intensive care unit support, so prompt recognition of these syndromes could avoid unnecessary antibiotics and procedures.…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia

West

Sheeti

Mackay

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background Daptomycin pulmonary eosinophilia (DPE) has been well described in case reports and reporting from the Food and Drug Administration. We report 3 eosinophilic syndromes associated with daptomycin use. Methods This is a retrospective review of all patients who received daptomycin (inpatient or outpatient) from 2010 to 2020 at the Veterans Affairs Portland Healthcare System. Patients who developed DPE while receiving daptomycin were evaluated to determine risk factors. Data collected included daptomycin dose and duration, body mass index, creatinine clearance, and peripheral eosinophilia. Results Of 330 patients who received daptomycin, 81.5% developed a peripheral eosinophilia, with 109 (33%) developing peripheral eosinophilia ≥5%. Fifty-one (16%) met criteria for DPE. Primary DPE occurred in 38 of the 51 patients with a median 26 days of treatment, and 49% had peripheral eosinophilia ≥5%. Re-exposure DPE occurred in the other 13 patients and occurred a median of 3 days after initiation of daptomycin. The presence of an elevated peripheral eosinophilia of ≥5% during daptomycin usage was significantly associated with primary (odds ratio [OR], 2.23; 95% CI, 1.2–4.09; P = .008) and re-exposure DPE (OR, 12; 95% CI, 1.6–103; P = .003). All patients recovered after withdrawal of daptomycin without complications. Conclusions There are 3 daptomycin eosinophilic syndromes: peripheral eosinophilia, primary DPE occurring about 4 weeks into therapy, and re-exposure DPE. Elevated peripheral eosinophilia ≥5% was a risk factor for both primary and re-exposure DPE, but still identified about half the cases. Peripheral eosinophilia should be carefully monitored during daptomycin treatment, and clinicians should be aware that prior eosinophilia may predict an acute pulmonary reaction upon daptomycin re-exposure.

show abstract

Section: Discussionmentioning

confidence: 99%

Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia

West

Sheeti

Mackay

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series

Gidari,

Pallotto,

Francisci

2024

Infection

View full text Add to dashboard Cite

Purpose Daptomycin-induced eosinophilic pneumonia (DIEP) is a rare yet severe adverse event that requires rapid recognition and management. Diagnosing a definite case is challenging and involves meeting the American Thoracic Society (ATS) criteria, although alternative criteria have been suggested. This study aims to conduct a systematic review of literature and includes a case series. Methods Six cases of DIEP identified at Perugia Hospital, Perugia, Italy have been described. A systematic review was carried out adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines. Results a total of 74 cases of DIEP were analysed. Using ATS clinical criteria, 15 were classified as definite (20.3%), 54 as probable (73.0%), and 5 as possible (6.8%). Phillips criteria and the Lyon Algorithm identified 43/74 (58.2%) and 64/67 (95.5%) cases as definite, respectively. Bronchoalveolar lavage (BAL) was performed in 43 cases, revealing an average eosinophil count of 28.6% (SD 24.4). Radiological findings highlighted recurring features like bilateral opacities (68.1%), ground-glass opacities (41.7%), patchy infiltrates (30.6%), and peripheral predominance (19.4%). Upon suspicion, daptomycin was discontinued; 20 cases required no additional treatment, 38 received corticosteroids, and 12 received both corticosteroids and antibiotics. Recovery rates were high across all treatment types (≥ 73.7%). Most reports described rapid improvement post-withdrawal (within 96 h). Conclusions DIEP is a rare, fast-progressing condition where early diagnosis and prompt treatment are vital. Diagnosis relies on clinical, laboratory, and radiological evaluations. Stopping daptomycin is essential, with corticosteroids often necessary. Further research is needed to enhance diagnostic accuracy for this disease.

show abstract

Blood culture-negative prosthetic valve endocarditis and daptomycin-associated eosinophilic pneumonia: A case report

Fujii¹,

Arita²,

Uejima³

et al. 2022

Journal of Cardiology Cases

View full text Add to dashboard Cite

Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses

Cited by 5 publications

References 11 publications

Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia

Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia

Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series

Blood culture-negative prosthetic valve endocarditis and daptomycin-associated eosinophilic pneumonia: A case report

Contact Info

Product

Resources

About